Skip to main content
Erschienen in:

10.02.2022 | main topic

Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate

verfasst von: Klaus Berek, Claudia Paganini, Harald Hegen, Gabriel Bsteh, Astrid Grams, Michael Auer, Thomas Berger, Florian Deisenhammer, Franziska Di Pauli, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2022

Einloggen, um Zugang zu erhalten

Summary

Background

Natalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven.

Case presentation

We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.

Conclusion

Use of natalizumab during pregnancy may be an option in highly active multiple sclerosis.
Literatur
2.
Zurück zum Zitat Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365–77.CrossRefPubMed Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365–77.CrossRefPubMed
3.
Zurück zum Zitat Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.CrossRefPubMed Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.CrossRefPubMed
4.
Zurück zum Zitat Simone IL, Tortorella C, Ghirelli A. Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol. 2021;12:697974.CrossRefPubMedPubMedCentral Simone IL, Tortorella C, Ghirelli A. Influence of pregnancy in multiple sclerosis and impact of disease-modifying therapies. Front Neurol. 2021;12:697974.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Guger M, Traxler G, Drabauer M, Leitner-Pohn D, Enzinger C, Leutmezer F, et al. Pregnancy outcomes in patients with multiple sclerosis exposed to natalizumab‑A retrospective analysis from the Austrian multiple sclerosis treatment registry. Front Neurol. 2020;11:676.CrossRefPubMedPubMedCentral Guger M, Traxler G, Drabauer M, Leitner-Pohn D, Enzinger C, Leutmezer F, et al. Pregnancy outcomes in patients with multiple sclerosis exposed to natalizumab‑A retrospective analysis from the Austrian multiple sclerosis treatment registry. Front Neurol. 2020;11:676.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Landi D, Marfia GA. Exposure to natalizumab during pregnancy and lactation is safe—Yes. Mult Scler. 2020;26(8):887–9.CrossRefPubMed Landi D, Marfia GA. Exposure to natalizumab during pregnancy and lactation is safe—Yes. Mult Scler. 2020;26(8):887–9.CrossRefPubMed
8.
Zurück zum Zitat Peng A, Qiu X, Zhang L, Zhu X, He S, Lai W, et al. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. J Neurol Sci. 2019;396:202–5.CrossRefPubMed Peng A, Qiu X, Zhang L, Zhu X, He S, Lai W, et al. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. J Neurol Sci. 2019;396:202–5.CrossRefPubMed
9.
Zurück zum Zitat Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018;90(10):e823–e31.CrossRefPubMed Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018;90(10):e823–e31.CrossRefPubMed
10.
Zurück zum Zitat Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology. 2018;90(10):e832–e9.CrossRefPubMed Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology. 2018;90(10):e832–e9.CrossRefPubMed
11.
Zurück zum Zitat Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150.CrossRefPubMedPubMedCentral Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205.CrossRefPubMed Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205.CrossRefPubMed
13.
Zurück zum Zitat Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5.CrossRefPubMed Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5.CrossRefPubMed
14.
Zurück zum Zitat Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: The role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85(8):845–50.CrossRefPubMed Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: The role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85(8):845–50.CrossRefPubMed
15.
Zurück zum Zitat Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5.CrossRefPubMedPubMedCentral Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63.CrossRefPubMed Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63.CrossRefPubMed
17.
Zurück zum Zitat Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008;118(1):24–8.CrossRefPubMed Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008;118(1):24–8.CrossRefPubMed
18.
Zurück zum Zitat De Las Heras V, De Andres C, Tellez N, Tintore M. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler. 2007;13(8):981–4.CrossRefPubMed De Las Heras V, De Andres C, Tellez N, Tintore M. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler. 2007;13(8):981–4.CrossRefPubMed
19.
Zurück zum Zitat Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):117–30.CrossRefPubMed Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):117–30.CrossRefPubMed
20.
Zurück zum Zitat Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.CrossRefPubMedPubMedCentral Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170–7.CrossRefPubMed Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170–7.CrossRefPubMed
22.
Zurück zum Zitat Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627–34.CrossRefPubMed Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627–34.CrossRefPubMed
23.
Zurück zum Zitat Gonzalez-Suarez I, Rodriguez de Antonio L, Orviz A, Moreno-Garcia S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e671.CrossRefPubMedPubMedCentral Gonzalez-Suarez I, Rodriguez de Antonio L, Orviz A, Moreno-Garcia S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e671.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Guilloton L, Pegat A, Defrance J, Quesnel L, Barral G, Drouet A. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. J Gynecol Obstet Hum Reprod. 2017;46(3):301–2.CrossRefPubMed Guilloton L, Pegat A, Defrance J, Quesnel L, Barral G, Drouet A. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. J Gynecol Obstet Hum Reprod. 2017;46(3):301–2.CrossRefPubMed
25.
Zurück zum Zitat Ciron J, Hautecoeur P, Mathis S, Neau J. Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery. Rev Neurol. 2015;172(2):165–6.CrossRefPubMed Ciron J, Hautecoeur P, Mathis S, Neau J. Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery. Rev Neurol. 2015;172(2):165–6.CrossRefPubMed
26.
Zurück zum Zitat De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand. 2015;131(5):336–40.CrossRefPubMed De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand. 2015;131(5):336–40.CrossRefPubMed
27.
Zurück zum Zitat O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–65.CrossRefPubMed O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–65.CrossRefPubMed
28.
Zurück zum Zitat Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis:‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19(2):106–14.CrossRefPubMed Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis:‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19(2):106–14.CrossRefPubMed
29.
Zurück zum Zitat Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15(2):115–27.CrossRefPubMed Sandman L, Granger BB, Ekman I, Munthe C. Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012;15(2):115–27.CrossRefPubMed
30.
Zurück zum Zitat Beauchamp TL, Childress JF. Principles of biomedical ethics. Oxford: Oxford University Press; 1979. Beauchamp TL, Childress JF. Principles of biomedical ethics. Oxford: Oxford University Press; 1979.
31.
Zurück zum Zitat Robertson L. Contemporary interpretation of informed consent: autonomy and paternalism. Br J Hosp Med (Lond). 2016;77(6):358–61.CrossRef Robertson L. Contemporary interpretation of informed consent: autonomy and paternalism. Br J Hosp Med (Lond). 2016;77(6):358–61.CrossRef
32.
Zurück zum Zitat Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015;372(9):855–62.CrossRefPubMed Grady C. Enduring and emerging challenges of informed consent. N Engl J Med. 2015;372(9):855–62.CrossRefPubMed
Metadaten
Titel
Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate
verfasst von
Klaus Berek
Claudia Paganini
Harald Hegen
Gabriel Bsteh
Astrid Grams
Michael Auer
Thomas Berger
Florian Deisenhammer
Franziska Di Pauli, MD, PhD
Publikationsdatum
10.02.2022
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2022
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00913-6

Weitere Artikel der Ausgabe 15-16/2022

Wiener Medizinische Wochenschrift 15-16/2022 Zur Ausgabe